Medincell shares fall 7.5% over the week and return to their MM20
The Montpellier-based biopharmaceutical company regains some momentum mid-morning, in a Paris market trending lower. The stock is losing ground after a several-week rebound driven by sales of its flagship treatment in the United States.
Medincell loses 2.53% to €27.76, versus €28.48 at the previous day's close, while the SBF 120 falls 1.06% and the CAC 40 by the same magnitude. Over one week, the stock drops 7.47%, interrupting the sequence that began in early November, when it had crossed €29.06.
The price is thus at the level of the MM20 (€27.69), just 0.25% above it, while the MM50 (€25.55) and the MM200 (€25.04) remain well below, more than 8% away from the price. The RSI at 52 is neutral: the move of the day looks more like a pause than a reversal.
Uzedy sales, the driver of the rebound since early November
Over one month, the stock still shows a gain of 7.93%, following Teva's publication of Uzedy net sales of $85 million in the third quarter, up 96% year on year (published on November 3). Teva immediately raised its annual forecast to $290-310 million, compared with $270-290 million previously.
Over one year, the stock nonetheless remains down 8.8%. On the technical side, the €24.86 zone acts as support, with resistance at €30. Analyst consensus and price targets on Medincell are available on the site.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: T4 2025
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.